Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biondo Focus Fund Investor Class (BFONX)

17.43
Net Asset Value
-0.17%
1 Day
+7.73%
Year-to-Date
Overall Morningstar Rating
Large growth
Style or Category
No Load
Sales Expenses
2.66%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund invests primarily in a combination of long and short positions in (1) common stock of U.S. companies of any capitalization; (2) American depositary receipts ("ADRs") representing common stock of foreign companies; (3) investment grade fixed income securities; (4) exchange-traded funds and (5) options on common stock, ADRs and ETFs. It may also employ leverage including bank borrowing of up to 33% of the fund's assets (defined as net assets plus borrowing for investment purposes). The fund is non-diversified.

Performance

1 month+3.87% 3 years+29.48%
3 months+11.59% 5 years+13.51%
1 year+14.30% Since inception+10.29%
Data through --

Peer Comparisonvs. Large growth

 BFONXCategory
Performance 5-yr return+13.51%+16.96%
Expense ratio2.66%1.20%
Risk 5 year sharpe ratio0.681.23
Net assets$30.6M$2.7B
Average market cap$36.7B$76.4B
Average P/E24.321.4
Portfolio turnover52%52%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyBiondo Investment Advisor
Fund manager & tenureJoseph Biondo, Sr. / 5 Years
Minimal initial investment$1,000.00
Minimum IRA investment$500.00

Holdings

U.S. stock110.62%
International stock0.31%
Fixed income0.00%
Cash0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 32.03%
Financial service 21.84%
Hardware 16.61%
Consumer goods 15.35%
Industrial materials 7.19%
Top 10 Holdings
Portfolio weighting
-- 12.77%
ILMN Illumina Inc10.73%
PCRX Pacira Pharmaceuticals Inc10.18%
CELG Celgene9.31%
GILD Gilead Sciences9.13%
AAPL Apple8.48%
CMRX Chimerix Inc8.17%
MA MasterCard7.51%
FB Facebook5.80%
ISRG Intuitive Surgical4.76%